Answers are grounded in this paper and cite their sources.
Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: